This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Believe Surgery Partners (SGRY) Could Rally 39.04%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Surgery Partners (SGRY) points to a 39% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Company News for Feb 27, 2024
by Zacks Equity Research
Companies in The News Are: DPZ,FRPT,SGRY,ITRI
The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Surgery Partners, Nvidia and Occidental Petroleum
by Zacks Equity Research
Microsoft, Amazon.com, Surgery Partners, Nvidia and Occidental Petroleum are part of the Zacks top Analyst Blog.h
Warren Buffett's Annual Letter: Key Insights for Investors
by Sanghamitra Saha
Follow Warren Buffett's latest tips and bet on top-ranked stocks like Microsoft (MSFT), Amazon.com (AMZN), Surgery Partners (SGRY) and Nvidia (NVDA).
Here's What Key Metrics Tell Us About Surgery Partners (SGRY) Q4 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Surgery Partners (SGRY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Surgery Partners (SGRY) Beats Q4 Earnings Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 18.92% and 0.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Gear Up for Surgery Partners (SGRY) Q4 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Surgery Partners (SGRY) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
InnovAge Holding Corp. (INNV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of 0% and 4.07%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Surgery Partners (SGRY) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Surgery Partners (SGRY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Hologic's (HOLX) Q1 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Hologic's (HOLX) Breast Health segment registered strong growth in Q1, primarily owing to higher capital equipment revenues.
Will a Fall in Medicaid Customers Hurt Molina's (MOH) Q4 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q4 performance is likely to have been hurt by escalating medical care costs, and a decline in Medicaid and Marketplace membership, partly offset by growing Medicare premiums.
Boston Scientific (BSX) Q4 Earnings Top, Operating Margin Falls
by Zacks Equity Research
Boston Scientific (BSX) sees an increase in organic and operational revenues in its core business segments and geographies in the reported quarter.
ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed's (RMD) Q2 results reflect cost discipline to support an acceleration in profitability.
Abbott's (ABT) Q4 Earnings Match Estimates, Margins Rise
by Zacks Equity Research
Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.
Will the Individual MA Unit Aid Humana's (HUM) Q4 Earnings?
by Zacks Equity Research
Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.
Compared to Estimates, Surgery Partners (SGRY) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Surgery Partners (SGRY) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Surgery Partners (SGRY) Soars 9.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Surgery Partners (SGRY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Surgery Partners (SGRY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ensign Group (ENSG) Pursues Facility Buyouts in South Carolina
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in South Carolina to offer enhanced healthcare services to the state's residents.
Select Medical (SEM) Up 18% Year to Date: More Room to Run?
by Zacks Equity Research
Select Medical (SEM) is well-poised for growth on the back of a credible healthcare facility portfolio built through buyouts and JVs coupled with strong cash-generating abilities.
Zacks Industry Outlook Highlights Medpace, HealthEquity and Surgery Partners
by Zacks Equity Research
Medpace, HealthEquity and Surgery Partners are part of the Zacks Industry Outlook article.
3 Medical Services Stocks Countering Industry-Wide Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and SGRY are set to gain the most. However, staffing shortages may disrupt the trend.
Down -22.17% in 4 Weeks, Here's Why Surgery Partners (SGRY) Looks Ripe for a Turnaround
by Zacks Equity Research
Surgery Partners (SGRY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Molina Healthcare (MOH) Wins Medicaid Deal From New Mexico HSD
by Zacks Equity Research
Molina Healthcare (MOH) receives a contract from the New Mexico HSD, subsequent to which it can effectively serve the statewide Medicaid members.
New Strong Buy Stocks for August 15th
by Zacks Equity Research
SGRY, DFH, CDRE, DHI and KB have been added to the Zacks Rank #1 (Strong Buy) List on August 15, 2023.